Surface Modification of Poly(dimethylsiloxane) Blood Flow Chambers with a Poly(ethylene glycol) Conjugate and Factor XII Inhibitor

This study is focused on the application of a dual surface coating on poly(dimethylsiloxane) (PDMS) flow chambers, which aims to inhibit the contact activation pathway of coagulation. Polyethylene glycol (PEG) is a commonly used biocompatible molecule due to its hydrophilic nature and capacity to re...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:Langmuir : the ACS journal of surfaces and colloids. - 1985. - 41(2025), 8 vom: 04. März, Seite 5048-5059
1. Verfasser: DeMeulemeester, Jake A (VerfasserIn)
Weitere Verfasser: Thompson, Alex J, Potkay, Joseph A
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2025
Zugriff auf das übergeordnete Werk:Langmuir : the ACS journal of surfaces and colloids
Schlagworte:Journal Article Dimethylpolysiloxanes Polyethylene Glycols 3WJQ0SDW1A baysilon 63148-62-9 Factor XII 9001-30-3 Plant Proteins Fibrinogen mehr... 9001-32-5 trypsin inhibitor, Zea mays
Beschreibung
Zusammenfassung:This study is focused on the application of a dual surface coating on poly(dimethylsiloxane) (PDMS) flow chambers, which aims to inhibit the contact activation pathway of coagulation. Polyethylene glycol (PEG) is a commonly used biocompatible molecule due to its hydrophilic nature and capacity to reduce protein adsorption. Corn trypsin inhibitor (CTI) is a selective inhibitor of Factor XII, which is the initial factor responsible for activating the intrinsic pathway of coagulation. By sequentially applying these two coatings to PDMS substrates, we expect the PEG-CTI coating to decrease blood clot formation and reduce fibrinogen deposition on surfaces compared to uncoated surfaces. Our results indicate that the PEG-CTI coating was successful in significantly reducing both cell adsorption and fibrinogen deposition to the surfaces of PDMS flow chambers. This study is a step toward applying PEG-CTI surface coatings to PDMS microfluidic artificial lungs, in which the surface interaction between the PDMS lungs and blood is a critical issue that must be mitigated to realize the full potential of this exciting therapeutic tool
Beschreibung:Date Completed 04.03.2025
Date Revised 04.03.2025
published: Print-Electronic
Citation Status MEDLINE
ISSN:1520-5827
DOI:10.1021/acs.langmuir.4c04106